Model 3 is adjusted for age, gender, baseline HbA1c or glucose, 2‐year HbA1c or glucose, fenofibrate or placebo allocation, systolic blood pressure, diabetes duration, prior cardiovascular disease, prior microvascular complications, baseline use of oral hypoglycemics, insulin, and antihypertensives. The gene discussed is INS; the disease is diabetes mellitus.